CSIC Delegation in the Region of Valencia

The KATRIN (Karlsruhe Tritium Neutrino Experiment) team has published the most accurate measurement to date of the upper limit of the neutrino mass in the journal Science, establishing it at 0.45 electronvolts (eV), less than a millionth of the mass of an electron. The KATRIN experiment, launched in 2018 in Germany, will finalise its neutrino mass measurement campaign this year, having reached 1,000 days of data acquisition.

While some studies have suggested that having a mother with Alzheimer's may increase the risk of developing the disease, a new study reveals that having a father with the disease may be related to a greater spread of tau protein in the brain, which is a sign of the disease. The study, published in Neurology, does not prove that having a father with Alzheimer's causes these brain changes; it only shows an association.

A set of articles published in Nature and Nature Methods draws a high-resolution map of the structure of and connections between the brain cells of mice. The map is based on data from a single cubic millimetre of brain and includes more than 200,000 cells, around 84,000 neurons and 524 million synaptic connections. Although this is a very small part of the mouse brain, it will help us understand how different types of cells work together.

An international team with Spanish participation has analysed the usefulness of a blood biomarker - the p-tau217 protein - for detecting Alzheimer's disease in 1,767 patients. According to the authors, who publish the results in the journal Nature Medicine, the test has detected the disease with high reliability in four hospital cohorts, as well as in a primary care cohort. They add that it is an assay that can be easily implemented in clinical laboratories and is already routinely used in some centres in Spain.

EMA’s human medicines committee has recommended not authorising the marketing of Kisunla (donanemab), a drug intended for the treatment of early-stage Alzheimer's disease. The committee considered that the benefits of this drug were not great enough to outweigh the risk of potentially fatal events. In recent years, several patients have died due to microbleeds in the brain.

An international team of scientists from the KM3NeT collaboration has detected the signal from the highest-energy cosmic neutrino to date, some 30 times higher than those previously detected. The result suggests that the particle came from beyond the Milky Way, although its precise origin has yet to be determined. The results are published in the journal Nature. 

Meeting in the city of Windoek (Namibia), the plenary of the IPBES - Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services - has ratified two new reports: the Nexus Assessment and the Transformative Change Assessment. Three of their authors explained the main findings and the changes they propose at a briefing organised by SMC Spain.

More than three-quarters of the earth's land surface experienced drier climates between 1990 and 2020 compared to the previous three decades, according to a new report by the United Nations Convention to Combat Desertification. Over the past 30 years, 40.6 percent of the global landmass, excluding Antarctica, is classified as drylands, three percentage points more than the previous three decades. The report, which is being presented at the COP16 on desertification being held in Riyadh, Saudi Arabia, also shows that 2.3 billion people were living in drylands in 2020, a population that could rise to 5 billion by 2100 under a worst-case climate change scenario.

The seventh Annual Report of the COSCE Transparency Agreement, prepared by the European Animal Research Association, which analyses transparency in the use of animals for scientific experimentation in Spain in 2023, was presented today. According to the document, transparency is consolidated among the signatory institutions -168 in 2024- and all of them publish a statement on their websites on the use of animals. Public mention of the number and species used stands at 47%, compared to 38% the previous year.

Less than four months after the European Medicines Agency recommended in July not to grant marketing authorisation for Leqembi™ (lecanemab) for the treatment of Alzheimer's disease, the EMA's Committee for Medicinal Products for Human Use (CHMP) has reassessed the available evidence to conclude that the benefits outweigh the risks.